Patrys Limited (PAB.AX) Release: First Plant-Based Production Of PAT-SM6
4/2/2014 9:04:32 AM
Melbourne, Australia; 2 April, 2014: Patrys Limited (ASX: PAB), a clinical stage biotechnology company, today announced that data on the production of PAT-SM6 in an easy-to-grow plant manufacturing system have been published in the leading peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS). The article titled "Expression and glycoengineering of functionally active hetero-multimeric IgM in plants" is currently available online ahead of a future print edition of the journal.
The study was the result of a research collaboration involving Patrys and the University of Natural Resources and Life Sciences, Vienna, Austria. The collaboration has focused on developing an alternative production system for the manufacture of IgM antibodies (using PAT-SM6) which might significantly reduce production costs while maintaining the quality and functionality of the antibody products.
The study found that relatively high quantities of PAT-SM6 IgM antibody can be made in an easy-to-grow plant manufacturing system. Further, functionality of antibodies very often depends on the attached sugars. It was shown that by modulating the properties of the plants, a process called in planta glycoengineering, this plant expression system can produce fully functional antibodies that are similar to the antibodies generated by the human body. The study demonstrated this novel plant-based process can be successfully applied to generate high yield, functional, human-like IgM antibodies.
“The exciting and novel data presented in this paper show, for the first time, that functional IgM antibodies can be made efficiently, quickly and highly cost-effectively in a plant-based system. We believe that such a manufacturing system holds real promise for the future and further work in this area is ongoing” said Dr. Frank Hensel, publication author and Vice President of Research and Development at Patrys.
Dr. Marie Roskrow, Patrys’ CEO added: “Patrys was the first company to be credited with the development of IgM antibodies in human PER.C6 cells. We are very excited that our lead product, PAT-SM6, is once again at the forefront of new discoveries and the results of this collaboration prove that the IgM class of antibodies, that Patrys is focused on, can become the immunotherapy of choice in the near future with the possibility of using different antibody production platforms.”
A summary of the study published in PNAS is available for download at:
Help employers find you! Check out all the jobs and post your resume.
comments powered by